Press Release - Reset Pharma

Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000

by dcress | Nov 1, 2023 | Press Release

Company may now initiate Phase 2b trial for treatment of demoralization syndrome in patients with cancer Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health...

Reset Pharmaceuticals Announces Appointment of Neuroscience Industry Leader Lisa Deschamps to the Board of Directors

by dcress | Nov 2, 2022 | Press Release

Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development and commercialization of novel clinical-stage treatments for patients suffering from mental illnesses related to life-altering diseases, today announces that...

Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board to Deliver Keynote Presentation at The End in Mind Virtual Conference

by dcress | Oct 14, 2021 | Press Release

Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board, will deliver a keynote presentation at The End in Mind virtual conference being held on October 14, 2021. In addition, Anthony Back,...

Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

by dcress | Jul 7, 2021 | Press Release

Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in psychedelics, named chair of Reset Pharmaceuticals’ Scientific...